Japan Entry Acceleration Program Welcomes Ten Global Companies in Regenerative Medicine

Japan Entry Acceleration Program: A Gateway for International Startups in Japan's Regenerative Medicine Sector

The Japan Entry Acceleration Program 2025, overseen by 01Booster in collaboration with JETRO (Japan External Trade Organization), is set to provide invaluable support to international startups looking to penetrate the Japanese market.

In an effort to boost co-innovation and business development, this initiative specifically targets companies in the regenerative medicine sector. The program offers expert mentoring, exposure opportunities like Demo Days, and facilitates partnerships with local CDMO (Contract Development and Manufacturing Organization) and CRO (Contract Research Organization) research foundations. This year, after a rigorous selection process, ten overseas firms have been chosen to participate.

Selected Companies and Their Innovations

1. Tidewave Biotech Inc. (USA)

Tidewave specializes in developing an off-the-shelf dendritic cell immunotherapy for solid tumors. Their innovative system merges gene-enhanced allogeneic cell products and rapid in-house specimen processing, allowing for immediate patient-specific antigen loading. This combination aims to achieve extensive neo-antigen targeting and T-cell activation.
Company Website

2. Ernexa Therapeutics (USA)

Focused on cell treatments for advanced cancers and autoimmune diseases, Ernexa produces allogeneic iPS-derived mesenchymal stem cells (iMSCs), eliminating the need for patient-derived cell collection. Their key products, ERNA-101 and ERNA-201, target ovarian cancer and inflammation in autoimmune diseases, respectively.
Company Website

3. Lift BioSciences Ltd (UK)

Lift is pioneering immune therapies against refractory cancers using immune-modulated alpha neutrophils (IMANs). By harnessing neutrophil characteristics for tumor infiltration and destruction, the company offers antigen-independent treatment options. Their scalable manufacturing approach supports multiple pipeline projects.
Company Website

4. Senti Biosciences, Inc. (USA)

This clinical-stage biotech firm is developing next-gen cell and gene therapies for tough-to-treat diseases. Utilizing a synthetic biology platform, Senti creates precision drugs through its